ClinicalTrials.gg
CompletedNCT06235151Solar-StageUpdated Nov 19, 2026

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer

A Phase 3 interventional study of Copper Cu 64 PSMA I&T in Prostate Cancer and Prostate Adenocarcinoma, sponsored by Curium US LLC. Completed at 43 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Curium US LLC · Phase 3, Interventional, and Diagnostic

How we know

Updated Nov 19, 2026Now CompletedEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
443
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 3,597 studies in Prostatic Neoplasms with a site in United States — 605 open to participants now, 974 under way, 100 of them phase 3. Prostatic Neoplasms · United States.

Enrollment
274th of 3,024
443 · median 48
Started
2024
with 174 others
Phase 3
284 of 3,597
41 open now
Registered
3,155th of 3,597
by date

Among the 3,597 studies in Prostatic Neoplasms with a site in United States, this one is the 274th largest by enrollment of the 3,024 interventional ones that give a count, is one of 175 that started in 2024, is one of 284 in phase 3, and was the 3,155th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

605 of the 3,597 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

600 more — sign in →

All 605 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,597 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.

Read the detailed description

The study will include approximately 439 patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer electing to undergo radical prostatectomy with pelvic lymph node dissection. Each patient will be administered an 8 mCi (± 10 percent) intravenous dose of copper Cu 64 PSMA I\&T injection. PET/CT imaging will be acquired for all patients at 1-4 hours ± 15 minutes post copper Cu 64 PSMA I\&T injection.

The PET/CT images will be interpreted independently by three readers blinded to all patient information. Each patient study will be assessed and scored for the detection of lesions considered positive for Prostate Cancer (PC) in pelvic lymph nodes. Positive lesions in the prostate, extra pelvic lymph nodes, bones and soft tissue/viscera will also be recorded. Analysis of the reads will be used for determination of sensitivity and specificity of copper Cu 64 PSMA I\&T PET/CT by comparison to the reference standard of histopathology after matching by hemipelvis with at least one true positive lesion defining a true positive patient. Detection of PC outside the pelvis on the copper Cu 64 PSMA I\&T PET/CT will be assessed using reference standard of histopathology and if not available conventional imaging. Baseline conventional imaging will be reviewed for PC disease or no disease by independent radiology readers.

03

Conditions studied

  • Prostate Cancer
  • Prostate Adenocarcinoma

Browse trials for

Keywords

  • PSMA
  • Prostate Cancer
  • Initial Staging
  • Solar-Stage
  • Cu-64 PSMA
  • PET
  • Solar
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with proven prostate adenocarcinoma.
  • Planned prostatectomy with pelvic lymph node dissection.
  • Unfavorable intermediate-risk, high-risk, or very high-risk disease defined by NCCN Guidelines Version 1.2023 and previous versions.
  • Male aged greater than or equal to 18 years.
  • Able to understand and provide signed written .

Exclusion criteria

Exclusion Criteria:

  • Androgen deprivation therapy, chemotherapy, radiation therapy (including local ablation techniques), or any therapy against Prostate Cancer (PC) prior to prostatectomy.
  • Patients participating in an interventional clinical trial within 30 days and having received an Investigational Product (IP) within five (5) biological half-lives prior to administration.
  • Patients with any medical condition or circumstance (including receiving an IP or not capable of having a PET study) that the investigator believes may compromise the data collected or lead to a failure to fulfill the study requirements.
  • Patients who are planned to have an x-ray contrast within 24 hours or other PET radiotracer within 10 physical half-lives prior to the PET scan. If Barium contrast is administered this should be cleared before the PET scan.
  • Patients who are administered any high energy (greater than 300 KeV) gamma emitting radioisotopes within five (5) physical half-lives prior to copper Cu 64 PSMA I\&T administration.
  • Patients with known to the active substance or any of the of the IP.
  • Patients who had a PSMA PET scan as part of their standard medical care within 90 days prior to enrollment.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
443 participants (actual)

Study arms

  • Experimental
    Diagnostic Imaging with Copper Cu 64 PSMA I&T

    Copper Cu 64 PSMA I\&T Injection

    Drug: Copper Cu 64 PSMA I&T

Interventions

06

What researchers measure

Primary outcomes

  1. Sensitivity

    Determine the presence of metastatic pelvic lymph nodes relative to histopathology reference standard. At least one positive pelvic lymph node on the PET scan and one positive lymph node as determined by histopathology on the same side of the pelvis (left or right) will be counted a true positive at the patient level.

    Time frame: 4 Hours

  2. Specificity

    Determine the absence of metastatic pelvic lymph nodes relative to histopathology reference standard. Negative pelvic lymph node on the PET scan and negative pelvic lymph nodes as determined by histopathology on the same side of the pelvis (Left or Right) will be counted a true negative at the patient level.

    Time frame: 4 Hours

Secondary outcomes

  1. Inter-reader and intra-reader agreement of copper Cu 64 PSMA I&T PET/CT interpretation on a per-patient basis

    Reader kappa statistics of copper Cu 64 PSMA I\&T PET/CT scan interpretation by the blinded independent readers.

    Time frame: 4 Hours

  2. Incidence of adverse events in copper Cu 64 PSMA I&T injection

    Treatment-emergent adverse events (AEs) will be assessed and graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: At time of dose administration up to 72 Hours

  3. Positive Predictive Value and Negative Predictive Value

    1\. To assess the Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of copper Cu 64 PSMA I\&T PET/CT

    Time frame: 4 hours

Other outcomes

  1. Determine the relationship of Prostate Specific Antigen (PSA) level, Gleason score, and the diagnostic performance of copper Cu 64 PSMA I&T PET/CT

    Correlation of sensitivity, specificity, detection rate, and Positive Predictive Value (PPV) to baseline PSA and unfavorable intermediate-risk, high-risk or very high-risk at the time of prostatectomy.

    Time frame: 4 Hours

  2. Assess PPV of lesions on copper Cu 64 PSMA I&T PET/CT outside the prostate and pelvic lymph nodes (M1 disease)

    Proportion of patients with M1 lesions on copper Cu 64 PSMA I\&T PET/CT subsequently confirmed to be TP by biopsy, surgery and confirmatory imaging.

    Time frame: 4 Hours

  3. Assess the impact of copper Cu 64 PSMA I&T PET/CT on the intended clinical management of study participants

    Percentage of patients in whom the copper Cu 64 PSMA I\&T PET/CT changed the intended patient management (major and other changes).

    Time frame: 4 Hours

  4. Assess the detection rate on patient level and split by pelvic lymph nodes and extra pelvic lesions

    Patient level positivity rates of copper Cu 64 PSMA I\&T split by pelvic lymph nodes and extra pelvic lesions.

    Time frame: 4 Hours

  5. Determine sensitivity and specificity by risk group (unfavorable intermediate, high, or very high risk)

    Determine the diagnostic performance of copper Cu 64 PSMA I\&T PET/CT for the detection of presence or absence of pelvic lymph node metastasis in pre-prostatectomy patients by risk group (unfavorable intermediate, high, or very high risk).

    Time frame: 4 Hours

07

Study locations

43 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Oct 2026, 30 months.

Of 127 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 30 months is below that.

Counting every sponsor, half of 266 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Sep 2026 → Oct 2026 and completion Sep 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2024
First posted
Jan 31, 2024
StartActual
Apr 1, 2024
Primary completionActual
Oct 30, 2026was Sep 2026
CompletionActual
Oct 30, 2026was Sep 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 19, 2026
Primary completion
Sep 2026→Oct 2026
Oct 27, 2026
Study completion
Sep 2026→Oct 2026
Oct 27, 2026
Enrollment
439 (estimated)→443 (actual)
Nov 19, 2026
Show all 2 updates
  1. Nov 19, 2026
    Active, not recruiting→Completed
    Enrollment 439 (estimated)→443 (actual)
    + 2 other changes: verification date and date precision
  2. Oct 27, 2026
    Primary completion Sep 2026→Oct 2026
    Study completion Sep 2026→Oct 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06235151
Lead sponsor
Curium US LLC
Responsible party
Sponsor
First posted
Jan 31, 2024
Start date
Apr 1, 2024
Primary completion
Oct 30, 2026
Completion
Oct 30, 2026
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Copper Cu 64 Zadavotide Guraxetan

Start the discussion